Back to search
PD-1 Refractory Advanced Melanoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PD-1 Refractory Advanced Melanoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which PD-1 Refractory Advanced Melanoma trials you may qualify forThe purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild…
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any…
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue…
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HE…
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that…
This phase 1/2 trial will be conducted in two parts. Part 1 (Dose Selection) is designed to find the dose of dapansutrile with acceptable tolerability in combin…